| NCT ID | NCT06347874 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Minnesota |
| Condition | Rib Fractures |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2025-01-10 |
| Primary Completion | 2027-02-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 48 participants in total. It began in 2025-01-10 with a primary completion date of 2027-02-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine if patients with rib fractures who undergo cryoablation of the intercostal nerves have improved pain control 7 days from procedure when compared to those who have a ESP catheter.
Eligibility Criteria
Inclusion Criteria: * Patients who are over 18 who have more than one ribs fractured. Exclusion Criteria: * Patients who have an exclusion to regional anesthesia. * Patients who are pregnant via self-report or pregnancy test if they take one. * Non-English speakers * Patients who have cold urticaria * Patients with bilateral fractures * Patients currently intubated
Contact & Investigator
Candace Nelson
✉ nelso377@umn.eduNeil Hanson
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT06347874 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rib Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06347874 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06347874 currently recruiting?
Yes, NCT06347874 is actively recruiting participants. Contact the research team at nelso377@umn.edu for enrollment information.
Where is the NCT06347874 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT06347874 clinical trial?
NCT06347874 is sponsored by University of Minnesota. The principal investigator is Neil Hanson at University of Minnesota. The trial plans to enroll 48 participants.